Literature DB >> 15072831

Hypermethylation of the PTEN gene in ovarian cancer cell lines.

Thomas Schöndorf1, Matthias P Ebert, Juliane Hoffmann, Martina Becker, Natasha Moser, Saziye Pur, Uwe-Jochen Göhring, Maria-Paz Weisshaar.   

Abstract

This study was performed to investigate the hypermethylation status of the PTEN gene in ovarian cancer. To this end, we incubated eight ovarian cancer cell lines with the demethylating agent 5-aza-2' deoxycytidine in three different concentrations for 5 days. Subsequently, the PTEN expression was quantified by both real time RT-PCR and quantitative western analyses. PTEN mRNA varied considerably in response to demethylation whereas PTEN protein concentrations remained constant in all cell lines except OAW42 cells (12.5%). The data suggest that PTEN is highly regulated at translational level. However, methylation of the PTEN gene plays a subordinate role in ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15072831     DOI: 10.1016/j.canlet.2003.10.028

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  15 in total

1.  PCR-SSCP-DNA sequencing method in detecting PTEN gene mutation and its significance in human gastric cancer.

Authors:  Chuan-Yong Guo; Xuan-Fu Xu; Jian-Ye Wu; Shu-Fang Liu
Journal:  World J Gastroenterol       Date:  2008-06-28       Impact factor: 5.742

2.  Methylation profile in benign, borderline and malignant ovarian tumors.

Authors:  K F Tam; V W S Liu; S S Liu; P C K Tsang; A N Y Cheung; A M W Yip; H Y S Ngan
Journal:  J Cancer Res Clin Oncol       Date:  2006-12-20       Impact factor: 4.553

3.  MiR-200a is involved in proliferation and apoptosis in the human endometrial adenocarcinoma cell line HEC-1B by targeting the tumor suppressor PTEN.

Authors:  Rong Li; Jun-Lin He; Xue-Mei Chen; Chun-Lan Long; De-Hui Yang; Yu-Bin Ding; Hong-Bo Qi; Xue-Qing Liu
Journal:  Mol Biol Rep       Date:  2014-01-12       Impact factor: 2.316

Review 4.  Minireview: epigenetic changes in ovarian cancer.

Authors:  Curt Balch; Fang Fang; Daniela E Matei; Tim H-M Huang; Kenneth P Nephew
Journal:  Endocrinology       Date:  2009-07-02       Impact factor: 4.736

5.  Promoter region methylation and loss of protein expression of PTEN and significance in cervical cancer.

Authors:  Qiufeng Qi; Yang Ling; Ming Zhu; Linyan Zhou; Meizhen Wan; Yanqing Bao; Yongping Liu
Journal:  Biomed Rep       Date:  2014-06-16

6.  Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma.

Authors:  John K Wiencke; Shichun Zheng; Nanette Jelluma; Tarik Tihan; Scott Vandenberg; Tanja Tamgüney; Rachel Baumber; Ramon Parsons; Kathleen R Lamborn; Mitchel S Berger; Margaret R Wrensch; Daphne Adele Haas-Kogan; David Stokoe
Journal:  Neuro Oncol       Date:  2007-05-15       Impact factor: 12.300

Review 7.  Epigenetic regulation of cancer-associated genes in ovarian cancer.

Authors:  Mi Jeong Kwon; Young Kee Shin
Journal:  Int J Mol Sci       Date:  2011-01-31       Impact factor: 5.923

8.  Epigenomics of ovarian cancer and its chemoprevention.

Authors:  Huaping Chen; Tabitha M Hardy; Trygve O Tollefsbol
Journal:  Front Genet       Date:  2011-10-04       Impact factor: 4.599

9.  Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples.

Authors:  Jean-Pierre Issa; Razelle Kurzrock; Ignacio I Wistuba; David J Stewart; Maria I Nunez; Jaroslav Jelinek; David Hong; Sanjay Gupta; Marcelo Aldaz
Journal:  Clin Epigenetics       Date:  2014-07-03       Impact factor: 6.551

Review 10.  Histones and their modifications in ovarian cancer - drivers of disease and therapeutic targets.

Authors:  Deborah J Marsh; Jaynish S Shah; Alexander J Cole
Journal:  Front Oncol       Date:  2014-06-12       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.